PHASE II STUDY OF CELECOXIB AND DOCETAXEL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH PROGRESSION AFTER PLATINUM-BASED THERAPY

INTRODUCTION: To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. METHODS: Patients with relapsed NSCLC received celecoxib 400 mg orally twice daily beginning 7 days...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Schneider, Bryan J., Kalemkerian, Gregory P., Kraut, Michael J., Wozniak, Antoinette J., Worden, Francis P., Smith, Daryn W., Chen, Wei, Gadgeel, Shirish M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771331/
https://ncbi.nlm.nih.gov/pubmed/19057272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818de1d2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi